Innovations in Lung Cancer Research Supported by Leading Institutions
In an exciting development for lung cancer research, the Lung Cancer Research Foundation (LCRF) has partnered with Boehringer Ingelheim to award three promising early career investigators. These grants, valued at $250,000 each for two years, focus on innovative approaches to treat HER2-mutated lung cancer, aiming to foster groundbreaking discoveries in this critical area of oncology.
The Award for Innovative HER2 Research
The 2025 LCRF | Boehringer Ingelheim Early Investigator Award zeroes in on the science of HER2 mutations, which are known to be significant drivers of malignancy. Recipients are tasked with developing new therapeutic strategies aimed at improving outcomes for patients with tumors exhibiting these mutations.
Insights from LCRF's Chief Scientific Officer
"There is a critical need to define how HER2 alterations drive cancer progression and contribute to both response and resistance," emphasized LCRF's Chief Scientific Officer, Antoinette Wozniak, MD. Her hope is that the funded projects will uncover vital information that can enhance the care provided to patients with HER2-altered tumors.
Supporting Early Career Scientists
Recognizing the importance of nurturing the next generation of researchers, Bjoern Rueter, Vice President of Clinical Development and Medical Affairs at Boehringer Ingelheim, expressed the organization's commitment to backing early career scientists. "We're proud to support scientists who have the potential to lead breakthroughs in cancer treatment," he stated, reflecting a belief that vibrant partnerships with organizations like LCRF will facilitate advancements in medicine.
Results of the Selection Process
Projects seeking funding underwent a thorough assessment by LCRF's Scientific Advisory Board, ensuring a high standard of research proposals. This process highlights the rigor involved in selecting projects that maximize the impact on lung cancer research.
Featured Recipients of the Award
The recipients of the 2025 award include:
Pinar Özden Eser, PhD
Broad Institute of MIT and Harvard
Identifying actionable targets to improve response to therapy among patients with HER2-driven NSCLC
Elizabeth Brunk, PhD
The University of North Carolina at Chapel Hill
Linking Structural DNA Variation to Therapeutic Response and Resistance in HER2-Mutated NSCLC
Paul Stockhammer, MD, PhD
Yale University
Molecular determinants of tumor growth and therapeutic response in ERBB2-mutant lung cancer
Funding Trends for Lung Cancer Research
In 2025, LCRF has funded a record 19 projects, amounting to $4.45 million, marking a significant year in funding thanks to the generous contributions from its donors. The foundation’s ongoing commitment to elevating lung cancer research is reflected through these initiatives.
The Importance of Early Funding
According to Kathryn O'Donnell, PhD, chair of LCRF's Scientific Advisory Board, early career funding is crucial for motivating scientists. With the growing uncertainties surrounding federal grants, support from nonprofits like LCRF is vital in sustaining momentum in lung cancer research.
About Lung Cancer Research Foundation
The Lung Cancer Research Foundation stands as a dedicated nonprofit organization aimed at transforming lung cancer outcomes. They strive to enhance survival rates and improve the quality of life for patients through innovative research funding. Over its history, LCRF has awarded nearly $53 million across 445 research grants, the largest sum allocated by any nonprofit focused on lung cancer.
Contact for More Information
For inquiries, contact Sheila Sullivan, Sr. Director of Marketing & Communications at the Lung Cancer Research Foundation at ssullivan@lcrf.org.
Frequently Asked Questions
What is the LCRF | Boehringer Ingelheim Early Investigator Award?
This award supports early career researchers focusing on novel treatment approaches for HER2-driven lung cancer.
How much funding do recipients receive?
Each recipient is granted $250,000 over two years to conduct their research projects.
Who are the award recipients for 2025?
The awardees include Pinar Özden Eser, Elizabeth Brunk, and Paul Stockhammer, all focusing on innovative HER2-related research.
What is the significance of HER2 mutations in lung cancer?
HER2 mutations are significant oncogenic drivers in lung cancer, influencing cancer growth and treatment response.
How does LCRF support lung cancer research?
LCRF funds innovative research projects aimed at preventing, diagnosing, treating, and ultimately curing lung cancer.
